# A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

> **NCT07428369** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 1570 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **DRUG:** Linvoseltamab
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Daratumumab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07428369
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-05
- **Primary completion:** 2038-05-21
- **Final completion:** 2038-05-21
- **Target enrollment:** 1570 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07428369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07428369, "A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07428369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*